Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving01:29

Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving

Mechanistic models play a crucial role in algorithms for numerical problem-solving, particularly in nonlinear mixed effects modeling (NMEM). These models aim to minimize specific objective functions by evaluating various parameter estimates, leading to the development of systematic algorithms. In some cases, linearization techniques approximate the model using linear equations.
In individual population analyses, different algorithms are employed, such as Cauchy's method, which uses a...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling Peak Expiratory Flow in Patients With Asthma and Quantifying Treatment Effects Using a Mixed-Effects Hidden Markov Model.

CPT: pharmacometrics & systems pharmacology·2026
Same author

MCMC Correction of Score-Based Diffusion Models for Model Composition.

Entropy (Basel, Switzerland)·2026
Same author

Confidence-based prediction of antibiotic resistance at the patient level.

mBio·2026
Same author

Evaluating the reliability and validity of the Questionnaire on Well-Being: a validation study for a clinically informed measurement of subjective well-being.

Cognitive behaviour therapy·2024
Same author

Differential Responders to a Mixed Meal Tolerance Test Associated with Type 2 Diabetes Risk Factors and Gut Microbiota-Data from the MEDGI-Carb Randomized Controlled Trial.

Nutrients·2023
Same author

A validity study of a work sample test of leadership behavior using supervisor and subordinate ratings as criteria.

Scandinavian journal of psychology·2023

Related Experiment Video

Updated: Jun 19, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

The Empirical Bayes Variational Autoencoder-A Neural ODE Approach for Population Modeling in Pharmacology.

Marcus Baaz1, Anders Sjöberg1,2, Mats Jirstrand1,2

  • 1Fraunhofer-Chalmers Centre, Gothenburg, Sweden.

CPT: Pharmacometrics & Systems Pharmacology
|June 17, 2026
PubMed
Summary

This study introduces an empirical Bayes variational autoencoder (VAE) for population pharmacokinetics, improving latent variable modeling. The VAE framework accurately captures population variability and covariate effects, outperforming fixed-prior models in simulations.

Keywords:
Variational inferenceempirical Bayesneural ODEspopulation modeling

More Related Videos

Inherent Dynamics Visualizer, an Interactive Application for Evaluating and Visualizing Outputs from a Gene Regulatory Network Inference Pipeline
10:44

Inherent Dynamics Visualizer, an Interactive Application for Evaluating and Visualizing Outputs from a Gene Regulatory Network Inference Pipeline

Published on: December 7, 2021

Related Experiment Videos

Last Updated: Jun 19, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
09:47

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Inherent Dynamics Visualizer, an Interactive Application for Evaluating and Visualizing Outputs from a Gene Regulatory Network Inference Pipeline
10:44

Inherent Dynamics Visualizer, an Interactive Application for Evaluating and Visualizing Outputs from a Gene Regulatory Network Inference Pipeline

Published on: December 7, 2021

Area of Science:

  • Pharmacometrics
  • Machine Learning
  • Computational Biology

Background:

  • Population pharmacokinetic (PK) modeling is crucial for understanding drug behavior in diverse patient groups.
  • Existing neural network approaches, like VAEs and neural ODEs, offer flexible frameworks but require refinement for complex PK data.
  • Integrating empirical Bayes methods with VAEs can enhance population PK modeling by enabling covariate-dependent priors and correlated latent representations.

Purpose of the Study:

  • To investigate an empirical Bayes VAE formulation for population PK modeling.
  • To evaluate the framework's ability to capture population structure, covariate effects, and individual variability.
  • To assess the model's predictive performance and diagnostic capabilities in simulations and a clinical dataset.

Main Methods:

  • Developed an empirical Bayes VAE integrating encoder-decoder architectures with covariate-dependent population priors.
  • Utilized controlled simulation studies to assess parameter recovery and population structure identification.
  • Applied the framework to a small clinical benchmark dataset for evaluating subject-specific predictions and model diagnostics.
  • Incorporated input-response normalization for improved extrapolation beyond training data.

Main Results:

  • The empirical Bayes VAE successfully captured population-level variability and covariate effects in simulations, outperforming a fixed-prior VAE baseline which showed biases.
  • Extrapolation beyond training dosing schedules demonstrated more stable predictive behavior with input-response normalization.
  • Diagnostic analyses revealed clear relationships between inferred latent variables and true parameters, with accurate estimation of observation noise.
  • Cross-validation in the clinical case study indicated predictive performance comparable to existing neural ODE-based methods.

Conclusions:

  • The combination of empirical Bayes inference and neural ODE-based decoders presents a feasible approach for population PK modeling.
  • The proposed VAE framework demonstrates potential for pharmacometric applications, offering improved handling of correlated latent variables and probabilistic inference.
  • This work serves as a methodological proof-of-concept, highlighting the capabilities and current limitations of variational neural approaches in pharmacometrics.